journal article·2021-03-03

Dual-Targeting Glycol Chitosan/Heparin-Decorated Polypyrrole Nanoparticle for Augmented Photothermal Thrombolytic Therapy

Ting-Yu Lu, Chih-Yu Chiang, Yu-Jui Fan, Pei-Ru Jheng, Edgar Daniel Quiñones, Kuan-Ting Liu, Shuo-Hsiu Kuo, Han Yun Hsieh, Ching-Li Tseng, Jiashing Yu, Er-Yuan Chuang

Publisher page

Abstract

Near-infrared (NIR)-light-modulated photothermal thrombolysis has been investigated to overcome the hemorrhage danger posed by clinical clot-busting substances. A long-standing issue in thrombosis fibrinolytics is the lack of lesion-specific therapy, which should not be ignored. Herein, a novel thrombolysis therapy using photothermal disintegration of a fibrin clot was explored through dual-targeting glycol chitosan/heparin-decorated polypyrrole nanoparticles (GCS-PPY-H NPs) to enhance thrombus delivery and thrombolytic therapeutic efficacy. GCS-PPY-H NPs can target acidic/P-selectin high-expression inflammatory endothelial cells/thrombus sites for initiating lesion-site-specific thrombolysis by hyperthermia using NIR irradiation. A significant fibrin clot-clearance rate was achieved with thrombolysis using dual-targeting/modality photothermal clot disintegration in vivo. The molecular level mechanisms of the developed nanoformulations and interface properties were determined using multiple surface specific analytical techniques, such as particle size distribution, zeta potential, electron microscopy, Fourier-transform infrared spectroscopy (FTIR), wavelength absorbance, photothermal, immunofluorescence, and histology. Owing to the augmented thrombus delivery of GCS-PPY-H NPs and swift treatment time, dual-targeting photothermal clot disintegration as a systematic treatment using GCS-PPY-H NPs can be effectively applied in thrombolysis. This novel approach possesses a promising future for thrombolytic treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Venous Thromboembolism Diagnosis and Management · Photoacoustic and Ultrasonic Imaging · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering, National Taiwan University, Taipei 10617, Taiwan

School of Biomedical Engineering; and International Ph. D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan

Graduate Institute of Biomedical Materials and Tissue Engineering; and International Ph. D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan

Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan

Funding

Ministry of Science and Technology, Taiwan

References (69)

Show source-provided references
1. 10.1146/annurev.bioeng.1.1.29910.1146/annurev.bioeng.1.1.299 ↗
2. 10.1161/STR.000000000000015810.1161/STR.0000000000000158 ↗
3. 10.1002/advs.20190137810.1002/advs.201901378 ↗
4. 10.1021/cr068028210.1021/cr0680282 ↗
5. 10.1007/s12274-016-1119-510.1007/s12274-016-1119-5 ↗
6. 10.1002/adhm.20170018110.1002/adhm.201700181 ↗
7. 10.3390/molecules2306125610.3390/molecules23061256 ↗
8. 10.2147/IJN.S16329910.2147/IJN.S163299 ↗
9. 10.1016/j.actbio.2019.06.05310.1016/j.actbio.2019.06.053 ↗
10. 10.1016/j.apsusc.2020.14680910.1016/j.apsusc.2020.146809 ↗
11. 10.1016/j.biomaterials.2020.12022910.1016/j.biomaterials.2020.120229 ↗
12. 10.1021/acsnano.8b0177210.1021/acsnano.8b01772 ↗
13. 10.1002/adfm.20170182410.1002/adfm.201701824 ↗
14. 10.3389/fimmu.2019.0285210.3389/fimmu.2019.02852 ↗
15. 10.1093/oxfordjournals.jbchem.a02141110.1093/oxfordjournals.jbchem.a021411 ↗
16. 10.1016/j.nantod.2015.06.00610.1016/j.nantod.2015.06.006 ↗
17. 10.1002/wnan.168210.1002/wnan.1682 ↗
18. Watson J. · 1999
19. 10.1016/j.jconrel.2019.12.00210.1016/j.jconrel.2019.12.002 ↗
20. 10.1039/D0BM00583E10.1039/D0BM00583E ↗
21. 10.2217/nnm.14.9910.2217/nnm.14.99 ↗
22. 10.1371/journal.pone.006199110.1371/journal.pone.0061991 ↗
23. 10.1681/ASN.201907067710.1681/ASN.2019070677 ↗
24. 10.1016/j.isci.2020.10084810.1016/j.isci.2020.100848 ↗
25. 10.1016/0022-2828(80)90016-410.1016/0022-2828(80)90016-4 ↗
26. 10.1007/BF0058534610.1007/BF00585346 ↗
27. 10.1055/s-0038-165421110.1055/s-0038-1654211 ↗
28. 10.1378/chest.101.4_Supplement.131S10.1378/chest.101.4_Supplement.131S ↗
29. 10.2147/tcrm.s439810.2147/tcrm.s4398 ↗
30. 10.1182/bloodadvances.201802629410.1182/bloodadvances.2018026294 ↗
31. 10.2967/jnumed.110.08585210.2967/jnumed.110.085852 ↗
32. 10.1126/scitranslmed.aaf737410.1126/scitranslmed.aaf7374 ↗
33. 10.1016/j.bbagen.2008.10.00810.1016/j.bbagen.2008.10.008 ↗
34. 10.1016/j.carbpol.2020.11683710.1016/j.carbpol.2020.116837 ↗
35. 10.3390/molecules2505103910.3390/molecules25051039 ↗
36. 10.1158/0008-5472.CAN-03-105410.1158/0008-5472.CAN-03-1054 ↗
37. 10.1016/j.jacc.2004.12.07110.1016/j.jacc.2004.12.071 ↗
38. 10.1016/j.solener.2016.09.02110.1016/j.solener.2016.09.021 ↗
39. 10.1007/s00011-010-0294-110.1007/s00011-010-0294-1 ↗
40. 10.3109/09537104.2012.69674610.3109/09537104.2012.696746 ↗
41. 10.1111/j.1538-7836.2011.04218.x10.1111/j.1538-7836.2011.04218.x ↗
42. 10.1116/6.000038010.1116/6.0000380 ↗
43. 10.1021/acsami.8b0967010.1021/acsami.8b09670 ↗
44. 10.1021/am503831m10.1021/am503831m ↗
45. 10.1016/j.jconrel.2012.07.03810.1016/j.jconrel.2012.07.038 ↗
46. 10.1038/s42003-019-0393-710.1038/s42003-019-0393-7 ↗
47. 10.1016/j.bbamcr.2014.11.02210.1016/j.bbamcr.2014.11.022 ↗
48. 10.1039/C6RA05825F10.1039/C6RA05825F ↗
49. 10.1016/j.ijbiomac.2016.11.05310.1016/j.ijbiomac.2016.11.053 ↗
50. 10.1088/1742-6596/733/1/01203910.1088/1742-6596/733/1/012039 ↗
51. 10.1016/j.jconrel.2016.06.01710.1016/j.jconrel.2016.06.017 ↗
52. 10.1166/jbn.2015.191310.1166/jbn.2015.1913 ↗
53. 10.1007/s10616-013-9658-z10.1007/s10616-013-9658-z ↗
54. 10.1155/2013/53629110.1155/2013/536291 ↗
55. 10.1016/j.ijpharm.2005.06.02510.1016/j.ijpharm.2005.06.025 ↗
56. 10.1016/0005-2728(85)90172-010.1016/0005-2728(85)90172-0 ↗
57. 10.1039/b708707a10.1039/b708707a ↗
58. 10.1021/acsami.9b0982410.1021/acsami.9b09824 ↗
59. 10.1016/j.jcis.2017.08.09710.1016/j.jcis.2017.08.097 ↗
60. 10.1007/s12274-017-1950-310.1007/s12274-017-1950-3 ↗
61. 10.1590/jvb.2014.05410.1590/jvb.2014.054 ↗
62. 10.1080/09537104.2019.170888410.1080/09537104.2019.1708884 ↗
63. Harari O. A. · J. Immunol. · 1999 · 163 · 686010.4049/jimmunol.163.12.6860 ↗
64. 10.1016/j.molmed.2004.02.00810.1016/j.molmed.2004.02.008 ↗
65. 10.3109/1541906940901419810.3109/15419069409014198 ↗
66. 10.1083/jcb.142.5.138110.1083/jcb.142.5.1381 ↗
67. 10.3390/jfb502004310.3390/jfb5020043 ↗
68. 10.1161/ATVBAHA.118.31139010.1161/ATVBAHA.118.311390 ↗
69. 10.1161/ATVBAHA.113.30160710.1161/ATVBAHA.113.301607 ↗